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ABSTRACT 
Objective. Our research aims to assess a possible connection between tumour 
localization and histological subtypes of grade II meningiomas.  
Material and methods. 143 patients with grade II WHO meningiomas underwent 
surgical resection in "Prof. Dr. N. Oblu" Emergency Clinical Hospital Iași between 1990 
and 2015. The collected data included: patient age, gender, tumour localization and 
histopathological diagnosis (atypical, clear cells and chordoid meningioma).  
Results. 135 (94.4%) of all 143 patients with grade II meningiomas were atypical 
meningiomas, 6 (4.2%) were cell clear meningiomas and only 2 (1.4%) were chordoid 
meningiomas. As concerns their distribution by gender, 79 (55.2%) were female and 
64 (44.8%) were male. Grade II meningiomas were most commonly located at 
convexity 49.7% (n=71), followed by skull base in 30.8% (n=44) of the cases and 
parasagittal/falcine in 14.7% (n=21) of the patients.  
Conclusions. The most common localization of grade II meningiomas was convexity, 
followed by skull base, parasagittal/falcine and intraventricular areas. We have also 
noticed that convexity meningiomas are more frequent in women, unlike the other 
anatomical localizations in which the male-female ratio is almost equal. Therefore, 
further research is necessary to determine the role of embryological, 
anatomopathological and genetic factors in underlying the connection between 
meningioma grade and anatomical localization. 
 
INTRODUCTION 
Meningiomas makes up about one third of all primary central nervous 
system tumours, being the most common brain tumour in adults over 
the age of 35 (1), with an incidence that has increased in recent years (2, 
3). As far as Romania is concerned, an increase in the number of 
intracranial meningiomas was noted in its North-Eastern region (where 
this research was conducted) over the 1990-2015 period (4).  
Although meningiomas are usually benign slow-growing tumours, their 
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histological aggressiveness may classify them in 
grade II or III tumours, according to the WHO 
classification (5, 6). Whereas grade II meningiomas 
only made up 5-7% of all types of meningiomas 
before the 2007 WHO classification (7), they currently 
make up more that 20% of all meningiomas (7, 8, 9). 
Grade II meningiomas include three histological 
subtypes: atypical, the most common, and also 
chordoid and clear cell meningiomas, the occurrence 
rate of which is considerably lower (10). 
Among the multiple prognostic factors that can 
predict meningioma grade prior to tissue diagnosis 
(11, 12), several studies also found the anatomical 
localization (13, 14). Thus, several authors noticed 
the predisposition of grade II meningiomas for 
cerebral convexity (13, 15, 16) (Figure 1). 
 
 
 
FIGURE 1. Preoperative and postoperative axial T1-weighted 
images with contrast of an atypical meningioma (Professor 
Poeata’s personal collection) 
 
The goal of our research was to analyze grade II 
meningiomas distribution in North-Eastern Romania 
over a 25-year period (1990-2015). The patients 
underwent surgery in "Prof. Dr. N. Oblu" Emergency 
Clinical Hospital of Iasi, the advantage of this hospital 
being the fact that it services the whole of North-
Eastern Romania, a region with a population of 
about 4 million inhabitants (17) (Figure 2). 
 
 
  
FIGURE 2. Preoperative coronal (A) and axial (B) T1-weighted images with contrast showing a left falcine meningioma. Postoperative 
images showing tumour bed after gross total resection (C) (Assoc. Professor Turliuc’s personal collection) 
 
MATERIAL AND METHODS 
We have evaluated 143 patients hospitalized in "Prof. 
Dr. N. Oblu" Emergency Clinical Hospital of Iași 
between 1990 and 2015, with histologically proven 
grade II meningiomas (atypical, clear cells and 
chordoid). Also, the histological samples have been 
reviewed according to the current WHO 2016 criteria 
(18). We have excluded all patients with type 2 
neurofibromatosis (2 patients) and those for whom 
we were unable to collect full information about 
tumors (16 patients). The collected data included:  
gender, age, anatomical localization and histopatho- 
logical diagnosis (Table I). In order to confirm the 
anatomical localization of grade II meningiomas, the 
surgeon’s operative notes were taken into 
consideration. As concerns the intracranial 
localization of meningiomas, they were divided into 
four main categories: (1) convexity, (2) 
parasagittal/falcine, (3) skull base and (4) 
intraventricular. 
 
RESULTS 
Of all 143 patients with meningiomas, 79 (55.2%) 
were female patients and 64 (44.8%) were male 
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patients. The male: female ratio was 1:1.2. As 
concerns patients distribution on demographic 
groups, more than half of them were in the 50-69 
year age group (58.1%, n=83). As for the distribution 
of meningiomas according to anatomical localiza-
tion, they occurred mostly: 49.7% (n=71) at convex- 
ity, 30.8% (n=44) at skull base, 14.7% (n=21) in the 
parasa g i t ta l / f a l c in e  a rea  a n d 4 . 9% (n =7 ) 
intraventricular. Most meningiomas were atypical 
(94.4%, n=135), followed by clear cell meningiomas 
(4.2%, n=6) and only 1.4% (n=2) were chordoid. All 
patient characteristics are shown in Table I. 
 
 
Characteristics  Grade II  
n (%) 
No. of patients 143 
Gender female 
male 
79 (55.2) 
64 (44.8) 
Age groups (years) 
 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
3 (2.1) 
9 (6.3) 
23 (16.1) 
42 (29.4) 
41 (28.7) 
22 (15.4) 
3 (2.1) 
Tumor localization 
 
Convexity 
Skull base 
Parasagittal/falcine 
Intraventricular 
71 (49.7) 
44 (30.8) 
21 (14.7) 
7 (4.9) 
Histological subtypes 
 
Atypical meningioma 
Clear cell meningioma 
Chordoid meningioma 
135 (94.4) 
6 (4.2) 
2 (1.4) 
 
TABLE 1. Characteristics of 143 patients with grade II meningioma 
 
DISCUSSION 
Our research revealed a predilection of grade II 
meningiomas for the convexity, as 49.7% (n=71) of 
them occurred in this area, which is consistent with 
similar studies (10, 14, 19, 20, 21, 22). Skull base  
meningiomas ranked second 30.8% (n=44), followed 
by the parasagittal/falcine and intraventricular 
localization (Table 1, Figure 3). The distribution of the 
anatomical localization of tumors on age groups was 
similar in both women and men.  
 
FIGURE 3. Incidence of Grade II meningiomas according to anatomical localization 
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Although previous studies have demonstrated a 
predilection of grade II meningiomas for cerebral 
convexity (13, 15, 16), a clear etiological connection 
between a particular meningioma grade and its 
anatomical localization could not be established. 
However, some authors consider that the 
histological grade of the tumor may be related to the 
meninges’ complex embryological origin, which has 
a variable neoplastic potential (23, 24, 25, 26). 
Among the first studies that demonstrated the 
predilection of grade II meningiomas for cerebral 
convexity were those conducted by Mahmood et al. 
and Maier et al. (27, 28). Also, Kane et al. later 
demonstrated that non-skull base tumors would 
have an increased risk for grade II meningiomas 
compared to skull base tumors (13). On the other 
hand, Zhou et al. noted that meningiomas located at 
the median line of the skull base are the least likely 
to be grade II or III (6), similar to other studies that 
have revealed that skull base meningiomas are more 
frequently meningothelial (29, 30) and are also lower 
grade at initial resection (15). This predilection of 
meningiomas for various anatomical localizations in 
the intracranial space could be explained by the 
distinct embryological origins of non-skull and skull-
base dura (14, 15, 30, 31). In this respect, various 
authors have demonstrated that meninges around 
the brainstem would arise from cephalic mesoderm, 
whereas telencephalic meninges arise from neural 
crest cells (25, 29, 32, 33). This differential meningeal 
embryogenesis resulted in the predominance of one 
arachnoid cell type over the other location, which 
accounts for the aggressive behavior of some 
meningiomas as compared to others in some 
anatomical localizations (15). However, genomic 
studies have shed light on intracranial locations and 
mutational patterns, as well as on the potential 
embryonic cancer stem cell-like origin (34). 
In a study on 110 patients with incidentally 
discovered meningiomas, Hashimoto et al. also 
noticed that non-skull base meningiomas have a 
more aggressive behavior and that skull base 
meningiomas do not tend to grow when compared 
to non-skull base meningiomas (35). Moreover, even 
when these tumors grow, the growth rate was 
significantly lower in terms of annual growth rate 
and percentage (35). Also, the same authors 
demonstrated that 60% of the skull base incidental 
meningiomas had an exponential pattern of growth, 
unlike non-skull base incidental meningiomas 
characterized by a 33% growth percentage (35). In 
conclusion, the authors recommend non-skull base 
meningioma follow-up by magnetic resonance 
imaging at shorter intervals. The authors mention 
that the results must be interpreted as most 
meningiomas fit both exponential and linear 
patterns statistically (35). 
In 2003, the same authors suggested that a loss 
of 1p was shown to be significantly correlated with 
malignant progression of meningiomas, analyzing 72 
grade II and III meningiomas, with fluorescence in 
situ hybridization and loss of heterozygosity analyses 
(35, 36). The authors also pointed out that skull base 
meningiomas had a significantly lower percentage of 
cells with 1p loss (20.31%) compared to non-skull 
base meningiomas (37.87%), suggesting that skull 
base tumors would have fewer genetic alterations 
and consequently would have less aggressive 
biological behavior (35). Similarly, Murphy et al. 
showed in their study that meningiomas originating 
at the convexity had more chromosomal 
abnormalities than those arise from skull base (37). 
In terms of histopathology, there have been 
studies that have shown its importance in the 
prediction of some types of meningiomas for certain 
intracranial localizations. Thus, McGovern et al., in a 
study of 216 patients with grade I, II and III 
meningiomas, claimed that grade I non-skull base 
meningiomas had a higher MIB-1 labeling index than 
grade I skull base meningiomas, suggesting that non-
skull base tumors may have a more aggressive 
biology (16). As concerns their recurrence, the same 
author noted that non-skull base meningiomas, 
when they recur, have a higher WHO grades than 
skull base meningiomas (16). Also, in 2018, Turk et al. 
concluded in a study of 40 grade I and II 
meningiomas that the skull base group had 
significantly higher CD34 levels than the non-skull 
base group, suggesting that skull base meningiomas 
tend to have higher microvascular density and are 
better vascularized than non-skull base tumors (38). 
As regards the distribution of meningiomas on 
genders in the overall number of patients, we 
revealed a male: female ratio of 1:1.2, with a slight 
predominance in females, in agreement with other 
literature studies (14, 19, 39). On the other hand, 
whereas in the skull base, intraventricular and 
parasagittal/falcine localizations the male: female 
ratio was approximately 1:1, location at convexity 
level was dominated by women, with a male: female 
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ratio of 1:1.5 (43/28) (Figure 4). In order to justify this 
predominance of women, research has shown that 
grade I meningiomas have a high level of 
progesterone receptor expression relative to grade II 
and III meningiomas, which seem to have a lower 
frequency of estrogen and androgen receptors (13, 
40, 41, 42), which means close male-female ratios. 
On the other hand, Morokoff et al. in a study of 163 
convexity meningiomas (grades I, II and III) noted a 
prevalence of the female sex, with a male: female 
ratio of 1:2.7 (43). In higher-grade meningiomas, 
Morokoff et al. found a male: female ratio of 1:1, 
much lower than our ratio of 1:1.5. 
 
 
FIGURE 4. Incidence of grade II meningioma according to gender  
With regard to the distribution of histological 
subtypes of grade II meningiomas, atypical 
meningiomas prevailed in our research (94.4%), 
followed by clear cell and chordoid meningiomas in 
a much lower percentage, as there are rare types of 
tumors (Table 1). 
Of all grade II meningiomas, atypical 
meningiomas are the most common, their 
percentage increasing to 20-30% of all meningiomas 
after the introduction of the WHO classification in 
2000 and 2007 (2, 8, 9). Like grade I or III 
meningiomas, atypical meningiomas may develop 
anywhere in the intracranial space, with some 
studies reporting a higher frequency of atypical 
meningiomas at the level of cerebral convexity (8, 27, 
44, 45). 
Clear cell meningioma is a rare disorder, as it 
makes up less than 1% of all meningiomas, and 
English-language literature reports 218 intracranial 
tumors (46). This percentage is also low in our 
research, with an incidence rate of this type of 
meningioma only 4.2% (n=6) over the 25-year period 
(Table I). Whereas previous studies revealed that the 
most common localization for clear cell meningioma 
was the cerebellopontine angle (47, 48, 49), all clear 
cell meningiomas in our group were located in the 
parasagittal/falcine area (n = 6). From this point of 
view, the results of the studies differ from each 
other: some studies show that the most affected 
location is convexity (46), whereas others point to 
skull base (50), particularly cerebellopontine angle, 
parasagittal tumors having lower occurrence rates 
(47). 
Chordoid meningiomas are also rare types of 
meningiomas, as only a little more than 100 cases 
are reported in literature (51, 52, 53, 54, 55, 56). Rare 
neoplasia with a unique chordoid appearance, 
chordoid meningioma has a predilection for the 
supratentorial localization (1, 57), similar to our study 
in which the two chordoid meningiomas had 
parasagittal/falcine localization. 
 
CONCLUSIONS 
Our study has shown a predominance of grade II 
meningiomas for cerebral convexity, which is the 
most common location in the intracranial space, 
followed by the skull base, parasagittal/falcine and 
intraventricular locations. We also noticed that 
convexity meningiomas predominate especially in 
women. Further research is needed to highlight the 
role of genetic, embryological and 
anatomopathological factors in highlighting the 
 237 Anatomical localization of intracranial grade II meningiomas in North-Eastern Romania 
connection between meningioma grade and 
anatomical localization 
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